Denali Total Liab vs Cash And Short Term Investments Analysis

DNLI Stock  USD 15.80  0.37  2.40%   
Denali Therapeutics financial indicator trend analysis is much more than just examining Denali Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Denali Therapeutics is a good investment. Please check the relationship between Denali Therapeutics Total Liab and its Cash And Short Term Investments accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Total Liab vs Cash And Short Term Investments

Total Liab vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Denali Therapeutics Total Liab account and Cash And Short Term Investments. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Denali Therapeutics' Total Liab and Cash And Short Term Investments is 0.86. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Denali Therapeutics, assuming nothing else is changed. The correlation between historical values of Denali Therapeutics' Total Liab and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Denali Therapeutics are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Total Liab i.e., Denali Therapeutics' Total Liab and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

0.86
Relationship DirectionPositive 
Relationship StrengthStrong

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Denali Therapeutics balance sheet. This account contains Denali Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Denali Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.
Most indicators from Denali Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Denali Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.The current Selling General Administrative is estimated to decrease to about 54.3 M. The current Tax Provision is estimated to decrease to -6,300
 2021 2022 2023 2024 (projected)
Interest Income4.6M14.8M51.5M54.1M
Net Interest Income4.6M14.8M45.0M47.3M

Denali Therapeutics fundamental ratios Correlations

0.910.750.990.490.960.89-0.75-0.790.430.850.640.720.640.980.650.920.50.930.930.940.90.790.770.980.66
0.910.770.910.210.910.88-0.53-0.890.570.670.490.770.530.910.590.870.280.890.920.960.790.840.660.910.59
0.750.770.69-0.040.670.67-0.41-0.670.310.520.720.640.860.670.40.690.040.680.860.740.830.540.470.680.43
0.990.910.690.460.980.88-0.71-0.820.50.820.610.760.580.970.710.930.450.940.910.950.820.810.830.980.72
0.490.21-0.040.460.440.38-0.760.01-0.250.720.09-0.080.070.540.220.360.970.290.210.290.510.20.330.530.22
0.960.910.670.980.440.87-0.69-0.810.510.790.560.750.560.960.570.940.450.940.910.950.80.80.760.960.57
0.890.880.670.880.380.87-0.5-0.810.480.670.570.680.530.870.640.940.450.880.890.910.80.890.770.870.64
-0.75-0.53-0.41-0.71-0.76-0.69-0.50.260.03-0.97-0.42-0.18-0.37-0.75-0.37-0.49-0.73-0.55-0.47-0.51-0.74-0.33-0.51-0.74-0.38
-0.79-0.89-0.67-0.820.01-0.81-0.810.26-0.83-0.46-0.45-0.95-0.41-0.78-0.59-0.84-0.04-0.93-0.87-0.9-0.59-0.94-0.62-0.78-0.6
0.430.570.310.5-0.250.510.480.03-0.830.170.340.87-0.030.40.410.53-0.220.720.50.580.190.80.350.410.4
0.850.670.520.820.720.790.67-0.97-0.460.170.50.360.40.850.460.640.720.720.610.650.830.550.580.850.47
0.640.490.720.610.090.560.57-0.42-0.450.340.50.550.670.470.50.630.10.60.640.560.640.460.580.470.51
0.720.770.640.76-0.080.750.68-0.18-0.950.870.360.550.440.680.530.8-0.060.890.830.830.520.850.560.680.55
0.640.530.860.580.070.560.53-0.37-0.41-0.030.40.670.440.560.350.620.080.480.760.590.710.260.510.560.38
0.980.910.670.970.540.960.87-0.75-0.780.40.850.470.680.560.620.890.550.90.890.930.860.780.741.00.63
0.650.590.40.710.220.570.64-0.37-0.590.410.460.50.530.350.620.60.120.610.560.660.410.60.890.621.0
0.920.870.690.930.360.940.94-0.49-0.840.530.640.630.80.620.890.60.40.920.950.960.790.850.770.90.61
0.50.280.040.450.970.450.45-0.73-0.04-0.220.720.1-0.060.080.550.120.40.310.270.330.590.260.240.550.12
0.930.890.680.940.290.940.88-0.55-0.930.720.720.60.890.480.90.610.920.310.90.930.760.930.710.910.62
0.930.920.860.910.210.910.89-0.47-0.870.50.610.640.830.760.890.560.950.270.90.970.840.80.690.890.58
0.940.960.740.950.290.950.91-0.51-0.90.580.650.560.830.590.930.660.960.330.930.970.780.860.760.930.67
0.90.790.830.820.510.80.8-0.74-0.590.190.830.640.520.710.860.410.790.590.760.840.780.620.50.860.42
0.790.840.540.810.20.80.89-0.33-0.940.80.550.460.850.260.780.60.850.260.930.80.860.620.630.790.61
0.770.660.470.830.330.760.77-0.51-0.620.350.580.580.560.510.740.890.770.240.710.690.760.50.630.740.89
0.980.910.680.980.530.960.87-0.74-0.780.410.850.470.680.561.00.620.90.550.910.890.930.860.790.740.63
0.660.590.430.720.220.570.64-0.38-0.60.40.470.510.550.380.631.00.610.120.620.580.670.420.610.890.63
Click cells to compare fundamentals

Denali Therapeutics Account Relationship Matchups

Denali Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets553.2M1.6B1.4B1.5B1.2B932.8M
Other Current Liab20.4M42.5M47.7M63.8M61.2M31.3M
Total Current Liabilities45.3M71.7M378.2M363.9M78.0M121.8M
Total Stockholder Equity394.9M1.2B962.3M1.0B1.0B712.9M
Other Liab44.1M317.9M5.1M858K986.7K937.4K
Net Tangible Assets394.9M1.2B962.3M1.0B1.2B612.3M
Property Plant And Equipment Net80.7M73.5M69.6M74.5M71.6M52.4M
Net Debt(10.6M)(443.0M)(234.9M)(157.7M)(74.9M)(78.6M)
Retained Earnings(425.6M)(354.4M)(645.0M)(971.0M)(1.1B)(1.1B)
Accounts Payable2.6M1.1M4.8M2.8M9.5M10.0M
Cash79.4M507.1M293.5M218.0M127.1M194.5M
Non Current Assets Total123.2M108.6M506.9M87.9M89.8M154.9M
Non Currrent Assets Other2.7M2.5M11.9M11.9M16.5M17.4M
Other Assets2.7M2.5M11.9M13.4M1.00.95
Cash And Short Term Investments415.4M1.5B865.4M1.3B1.0B757.9M
Common Stock Shares Outstanding95.6M112.7M121.5M125.5M137.4M86.7M
Liabilities And Stockholders Equity553.2M1.6B1.4B1.5B1.2B932.8M
Non Current Liabilities Total113.0M382.1M63.6M53.9M45.0M42.7M
Capital Surpluse774.2M818.8M1.5B1.6B1.8B1.9B
Other Current Assets14.7M20.3M30.6M36.1M26.9M18.9M
Other Stockholder Equity818.8M1.5B1.6B2.0B2.1B1.1B
Total Liab158.3M453.7M441.9M417.8M123.0M220.0M
Property Plant And Equipment Gross80.7M73.5M69.6M74.5M117.6M123.5M
Total Current Assets430.0M1.5B897.2M1.4B1.1B778.0M
Accumulated Other Comprehensive Income350K(245K)(2.5M)(6.9M)643K675.2K
Common Stock1.3M1.5M1.5M1.7M1.7M1.6M
Property Plant Equipment80.7M40.8M69.6M74.5M85.7M44.6M
Short Term Investments335.9M962.6M571.9M1.1B907.4M633.8M
Long Term Investments61.3M147.9M39.9M32.7M425.4M0.0
Non Current Liabilities Other467K471K379K382.1M435.9K414.1K
Net Invested Capital394.9M1.2B962.3M1.0B1.0B879.0M
Net Working Capital384.7M1.4B519.0M1.0B986.2M811.7M
Current Deferred Revenue18.7M23.5M320.3M290.1M333.6M350.2M
Capital Stock1.3M1.5M1.5M1.7M1.7M1.7M
Short Term Debt3.7M4.7M5.5M7.3M7.3M6.3M

Pair Trading with Denali Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Denali Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Denali Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Denali Stock

  0.65DRRX Durect Earnings Call This WeekPairCorr

Moving against Denali Stock

  0.49SBFMW Sunshine BiopharmaPairCorr
The ability to find closely correlated positions to Denali Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Denali Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Denali Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Denali Therapeutics to buy it.
The correlation of Denali Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Denali Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Denali Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Denali Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.06)
Revenue Per Share
2.406
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.09)
Return On Equity
(0.14)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.